Discover the complete record of transactions filed by Xie Jian, Chief Operating Officer. Director active across 1 companies, notably Fulgent Genetics, Inc.. Cumulatively, 38 reports have been logged. Total volume traded: €1.7m. The latest transaction was filed on 26 February 2026 (Retenue fiscale). Regulator: SEC (Form 4). The full history is free.
25 of 38 declarations
Xie Jian, also known as James Xie, is a co-founder and senior executive of Fulgent Genetics, Inc., a U.S.-listed company on NASDAQ. He has served as Chief Operating Officer since April 2018 and has also been President since May 2022. Company disclosures describe him as a long-standing member of the executive team since Fulgent’s founding, with meaningful contributions to the business through his leadership and commitment to the company’s growth and expansion. In his current role, he is responsible for managing global operations, product vision, and product engineering, with an emphasis on unifying functions across the organization to improve efficiency, support sustainable growth, and foster continuous innovation. Before becoming Chief Operating Officer, Xie Jian served as Vice President of Bioinformatics at Fulgent Genetics from the company’s inception. His earlier career includes a substantial tenure at Cogent, a publicly traded biometric identification services and products company, where he served as Senior Vice President from 1996 to 2011. That background suggests deep experience in technology-driven operations, bioinformatics, and the scaling of specialized product organizations. His academic background reinforces that profile. He earned a B.A. in Engineering from Chongqing University and holds two master’s degrees from the University of New South Wales: one in Industrial Engineering and one in Computer Science. This combination of engineering, computing, and operational leadership has positioned him as a key executive in Fulgent Genetics’ development. His notable contributions, as described by the company, center on operational leadership, product and engineering oversight, and helping guide the company’s expansion in genetic testing and sequencing services.